Fundraising Fox

Hemostemix

Blackfalds · Founded 2014 · 1 known investors

hemostemix.com ↗

Hemostemix is a clinical-stage regenerative medicine company developing ACP-01, an investigational autologous (patient-derived) stem cell therapy for vascular and ischemic conditions such as critical limb ischemia, peripheral arterial disease, ischemic cardiomyopathy, and heart failure. The company runs Phase I and Phase II clinical programs and is publicly traded (TSXV: HEM | OTCQB: HMTXF).

BiotechHealthtechLongevityMedical Devices

Founders & leadership

Hemostemix was founded in 2014 by Roger Bergersen.

RBRoger Bergersen
Roger BergersenFounder (of predecessor TheraVitae Inc.)
IS
Ina SarelVP, Research and Development
KM
Kyle MakofkaChief Restructuring Officer
DB
David BermanChief Financial Officer
AJ
Angus JenkinsNamed on SEC filing
DF
Don FriesenNamed on SEC filing
DL
David L. WoodNamed on SEC filing
TA
Thomas A. SmeenkPresident & CEO, Co-Founder
DF
Dr. Fraser HendersonChief Medical Officer

Investors · 1

BioBritLa Jolla

Reported raises · per SEC filings

Form D private placements
▶$132.1KofferedSep 2017 · 2 investors · Biotechnology
Rule 506(c)
Officers, directors & promoters on the filing
  • Angus JenkinsDirector
  • Don FriesenDirector
  • Ina SarelExecutive Officer
  • Kyle MakofkaExecutive Officer
  • David BermanExecutive Officer
  • David L. WoodDirector
Offering amount
$132.1K
First sale
Aug 2017
Incorporated
Corporation, Alberta, Canada, 2014
Federal exemptions
06c
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 2

by search overlap
American Endovascular12 shared keywordsOutpatient centers for treatment of peripheral artery disease.
Osmosis10 shared keywordsOsmosis is a US health education platform of short-form medical videos and learning tools, acquired by Elsevier.

Companies competing with Hemostemix for the same Google search keywords, organic and paid, via search-intersection analysis.

Frequently asked questions

What does Hemostemix do?
Hemostemix is a clinical-stage regenerative medicine company developing ACP-01, an investigational autologous (patient-derived) stem cell therapy for vascular and ischemic conditions such as critical limb ischemia, peripheral arterial disease, ischemic cardiomyopathy, and heart failure. The company runs Phase I and Phase II clinical programs and is publicly traded (TSXV: HEM | OTCQB: HMTXF).
Who founded Hemostemix?
Hemostemix was founded by Roger Bergersen in 2014.
Who are Hemostemix's investors?
Hemostemix's investors include BioBrit.
Where is Hemostemix headquartered?
Hemostemix is headquartered in Blackfalds.